Molecular Insight Pharmaceuticals, Inc. Announces Panel Participation at the BIO 2008 International Convention
June 11 2008 - 8:30AM
Business Wire
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced
today that John E. McCray, Chief Operating Officer of Molecular
Insight, will participate in a panel discussion on the strategic
in-licensing of late-stage compounds at the upcoming Biotechnology
Industry Organization (BIO) International Convention, being held
June 17-20, 2008 in San Diego, CA. The panel discussion, �Finding
the Late-stage Candidate of Your Dreams,� will explore how several
companies successfully in-licensed late-stage product candidates
from large pharmaceutical companies on terms that were acceptable
to management and shareholders and that promised excellent
potential returns. This panel will take place on Wednesday, June
18th from 10:15 a.m. to 11:45 a.m. Pacific Time in room 33ABC at
the San Diego Convention Center. About Molecular Insight
Pharmaceuticals, Inc. Molecular Insight Pharmaceuticals (NASDAQ:
MIPI) is a biopharmaceutical company specializing in the emerging
field of molecular medicine, applying innovations in the
identification and targeting of disease at the molecular level to
improve healthcare for patients with life-threatening diseases. The
company is focused on discovering, developing and commercializing
innovative, molecular radiotherapeutics and molecular imaging
pharmaceuticals with initial applications in the areas of oncology
and cardiology. Its lead molecular radiotherapeutic product
candidates, Azedra and Onalta, are being developed for detection
and treatment of cancer. The company's lead molecular imaging
pharmaceutical product candidate, Zemiva, is being developed for
the diagnosis of cardiac ischemia, or insufficient blood flow to
the heart. In addition, the company has a growing pipeline of
product candidates resulting from application of its proprietary
platform technologies to new and existing compounds. Molecular
Insight Pharmaceuticals is based in Cambridge, Massachusetts and
its website address is: www.molecularinsight.com. Forward-Looking
Statements Statements in this release that are not strictly
historical in nature constitute "forward-looking statements." Such
statements include, but are not limited to statements regarding the
development of AzedraTM, OnaltaTM, ZemivaTM and our other product
candidates. Such forward-looking statements involve known and
unknown risks, uncertainties, and other factors that may cause the
actual results of Molecular Insight to be materially different from
historical results or from any results expressed or implied by such
forward-looking statements. These factors include, but are not
limited to, risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval for product candidates; competition from other
pharmaceutical or biotechnology companies; and the additional risks
discussed in filings with the Securities and Exchange Commission.
All forward-looking statements are qualified in their entirety by
this cautionary statement, and Molecular Insight undertakes no
obligation to revise or update this news release to reflect events
or circumstances after the date hereof.
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
Historical Stock Chart
From Jul 2023 to Jul 2024